公开(公告)号：US20160158358A1

公开(公告)日：2016-06-09

申请号：US14852003

申请日：2015-09-11

Applicant: NOVARTIS AG

Inventor： Winfried ELIS ,  Seth ETTENBERG ,  Andrew Paul GARNER ,  Nicole HAUBST ,  Xizhong HUANG ,  Christian Carsten Silvester KUNZ ,  Elizabeth Anne REISINGER SPRAGUE ,  Qing SHENG

IPC: A61K39/395 ,  A61K45/06 ,  C07K16/32 ,  C07K16/28

CPC classification number: A61K39/39558 ,  A61K31/4439 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).

公开(公告)号：US20130330324A1

公开(公告)日：2013-12-12

申请号：US13693330

申请日：2012-12-04

Applicant: NOVARTIS AG

Inventor： Winfried ELIS ,  Seth ETTENBERG ,  Andrew Paul GARNER ,  Nicole HAUBST ,  Xizhong HUANG ,  Christian Carsten Silvester KUNZ ,  Elizabeth Anne REISINGER SPRAGUE ,  Qing SHENG

IPC: A61K39/395 ,  A61K45/06

CPC classification number: A61K39/39558 ,  A61K31/4439 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), whilst preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).

Abstract translation: 本发明涉及与HER受体家族例如HER3受体相互作用的抗体或其片段。 特别地，其涉及识别包含来自结构域2和4的残基的HER3受体的构象表位的抗体或其片段，导致抑制配体依赖性和与配体无关的信号转导; 并允许配体结合（例如神经调节蛋白），同时防止信号转导的配体诱导的激活。 这些抗体或片段可用于治疗以增加的HER3表达水平为特征的许多疾病或病症（例如食道癌）。 这些抗体或片段可用于治疗以减少组织重量（例如前列腺或子宫重量）或诱导组织萎缩（例如雄性乳房萎缩）为特征的抗体或片段能力的许多疾病或病症。

公开(公告)号：US20170362326A1

公开(公告)日：2017-12-21

申请号：US15073141

申请日：2016-03-17

Applicant: NOVARTIS AG

Inventor： Feng CONG ,  Seth ETTENBERG ,  Felix HARTLEPP ,  Ingo Markus KLAGGE

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  A61P35/00 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00

Abstract: The present invention relates to antibodies targeting LRP6 and compositions and methods of use thereof.

公开(公告)号：US20130251703A1

公开(公告)日：2013-09-26

申请号：US13693347

申请日：2012-12-04

Applicant: NOVARTIS AG

Inventor： Winfried ELIS ,  Seth ETTENBERG ,  Andrew Paul GARNER ,  Nicole HAUBST ,  Heather Adkins HUET ,  Christian Carsten Silvester KUNZ ,  Elizabeth Anne REISINGER SPRAGUE ,  Qing SHENG

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: A61K39/39558 ,  A61K31/4439 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention relates to antibodies or fragments thereof that bind to a non-linear epitope within domain 3 of the HER3 receptor and inhibit both ligand-dependent and ligand-independent signal transduction. The invention also relates antibodies or fragments thereof that bind to amino acid residues within domains 3-4 of HER3 and inhibit both ligand-dependent and ligand-independent signal transduction; and compositions and methods of use of such antibodies or fragments thereof.

Abstract translation: 本发明涉及与HER3受体的结构域3内的非线性表位结合并抑制配体依赖性和配体非依赖性信号转导两者的抗体或其片段。 本发明还涉及结合HER3的结构域3-4内的氨基酸残基并抑制配体依赖性和配体非依赖性信号转导两者的抗体或其片段; 以及使用这种抗体或其片段的组合物和方法。

公开(公告)号：US20150259426A1

公开(公告)日：2015-09-17

申请号：US14531569

申请日：2014-11-03

Applicant: NOVARTIS AG ,  Ablynx NV

Inventor： Karen CROMIE ,  Bruno DOMBRECHT ,  Seth ETTENBERG ,  Joost Alexander KOLKMAN ,  Jing LI ,  Kris MEERSCHAERT ,  Jingxin ZHANG

IPC: C07K16/28

CPC classification number: C07K16/2878 ,  A61K2039/505 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76

Abstract: The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also “DR5”), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as “NB agents”) and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders.

Abstract translation: 本发明涉及针对TRAIL细胞表面受体2（本文还称为“DR5”）的氨基酸序列以及编码它们的化合物或构建体，特别是编码它们的蛋白质和多肽和核苷酸（在本文中称为 其整体作为“NB剂”）及其片段及其药学上有效的变体，以及它们在诊断和治疗DR5相关疾病和病症中的用途。

公开(公告)号：US20130273029A1

公开(公告)日：2013-10-17

申请号：US13693339

申请日：2012-12-04

Applicant: NOVARTIS AG

Inventor： Winfried ELIS ,  Seth ETTENBERG ,  Andrew Paul GARNER ,  Christian Carsten Silvester KUNZ ,  Tobias SEITZ

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/92

Abstract: The present invention relates to antibodies or fragments thereof that target an epitope of a HER3 receptor residing in domain 2 of the HER3 receptor to block both ligand-dependent and ligand-independent signal transduction and tumor growth; and compositions and methods of use thereof.

Abstract translation: 本发明涉及靶向HER3受体结构域2中HER3受体表位的抗体或其片段，以阻断配体依赖性和配体非依赖性信号转导和肿瘤生长; 及其组合物和使用方法。